Lenvatinib Mesilate 99.0% Frontida
It is a first-line targeted drug for advanced liver cancer and has been approved in many countries. Its indications include thyroid cancer, advanced renal cell carcinoma and liver cancer.
About|Contact|Cas|Product Name|Molecular|Country|Encyclopedia
Message|New Cas|MSDS|Service|Advertisement|CAS DataBase|Article Data|Manufacturers | Chemical Catalog
©2008 LookChem.com,License: ICP
NO.:Zhejiang16009103
complaints:service@lookchem.com Desktop View